Heat Biologics Historical Balance Sheet

HTBX -  USA Stock  

USD 5.43  0.17  3.04%

Trend analysis of Heat Biologics balance sheet accounts such as Assets Non Current of 11.2 M or Cash and Equivalents of 10.6 M provides information on Heat Biologics' total assets, liabilities, and equity, which is the actual value of Heat Biologics to its prevalent stockholders. By breaking down trends over time using Heat Biologics balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year. Financial Statement Analysis is much more than just reviewing and breaking down Heat Biologics prevalent accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Heat Biologics is a good buy for the upcoming year.
Please check Risk vs Return Analysis.

Heat Biologics Historical Statements 


About Heat Biologics Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Heat Biologics at a specified time, usually calculated after every quarter, six months, or one year. Heat Biologics Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Heat Biologics and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Heat Biologics currently owns. An asset can also be divided into two categories, current and non-current.

Heat Biologics Balance Sheet Chart

Heat Biologics Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Heat Biologics uses and utilizes its capital. It also shows what exactly a company owns and owes.
Heat Biologics Current Liabilities is fairly stable at the moment as compared to the past year. Heat Biologics reported Current Liabilities of 3.66 Million in 2020. Trade and Non Trade Payables is likely to rise to about 1.2 M in 2021, whereas Accumulated Other Comprehensive Income is likely to drop (170.4 K) in 2021.

Total Assets

Total assets refers to the total amount of Heat Biologics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Heat Biologics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Major components are Cash and Equivalents; Investments; Goodwill and Intangible Assets; Property Plant and Equipment Net; [TaxAssets] and Trade and Non Trade Receivables.

Current Assets

Current assets of Heat Biologics include cash, cash equivalents, short-term investments, accounts receivable, stock inventory and the portion of prepaid liabilities which will be paid within a year. Depending on the nature of the business, current assets can range from barrels of crude oil, to baked goods, to foreign currency. Current assets are important because they are the assets that are used to fund day-to-day operations of Heat Biologics. The current portion of Total Assets; reported if a company operates a classified balance sheet that segments current and non-current assets.

Shareholders Equity

A principal component of the balance sheet; in addition to Total Liabilities and Total Assets; that represents the total of all stockholders' equity (deficit) items; net of receivables from officers; directors; owners; and affiliates of the entity which are attributable to the parent.

Total Liabilities

Deferred Income Tax is recorded on Heat Biologics balance sheet and a result of income already earned and recognized for accounting, but not tax, purposes. Also, differences between tax laws and accounting methods can result in a temporary difference in the amount of income tax payable by a company. This difference is recorded on Heat Biologics books as deferred income tax. Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Principal components are Total Debt; Deferred Revenue; Trade and Non Trade Payables; Deposit Liabilities; and Tax Liabilities.
Most accounts from Heat Biologics balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Heat Biologics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Please check Risk vs Return Analysis.Heat Biologics Current Liabilities is fairly stable at the moment as compared to the past year. Heat Biologics reported Current Liabilities of 3.66 Million in 2020. Trade and Non Trade Payables is likely to rise to about 1.2 M in 2021, whereas Accumulated Other Comprehensive Income is likely to drop (170.4 K) in 2021.
 2018 2019 2020 2021 (projected)
Current Assets28.71 M15.21 M113.79 M122.78 M
Total Assets37.76 M25.96 M124.19 M134 M

Heat Biologics balance sheet Correlations

Click cells to compare fundamentals

Heat Biologics Account Relationship Matchups

Heat Biologics balance sheet Accounts

201620172018201920202021 (projected)
Accumulated Other Comprehensive Income(72.23 K)(166.03 K)(19.9 K)(11.25 K)(166.06 K)(170.43 K)
Total Assets8.9 M20.19 M37.76 M25.96 M124.19 M134 M
Current Assets8.26 M11.75 M28.71 M15.21 M113.79 M122.78 M
Assets Non Current633.58 K8.44 M9.05 M10.75 M10.4 M11.22 M
Cash and Equivalents8.01 M9.84 M22.51 M9.43 M11.05 M10.6 M
Cash and Equivalents USD8.01 M9.84 M22.51 M9.43 M11.05 M10.6 M
Shareholders Equity8.8 M7.37 M30.29 M13.57 M116.24 M125.42 M
Shareholders Equity USD8.8 M7.37 M30.29 M13.57 M116.24 M125.42 M
Investments10.7 M6.69 M5.57 M5.71 M100.84 M108.8 M
Investments Current10.7 M6.69 M5.57 M5.71 M100.84 M108.8 M
Total Liabilities2.06 M14.41 M7.52 M12.8 M8.7 M8.7 M
Current Liabilities1.6 M10.34 M4.87 M8.44 M3.66 M4.52 M
Liabilities Non Current461.43 K4.07 M2.65 M4.36 M5.04 M4.18 M
Trade and Non Trade Payables290.06 K1.03 M974.62 K1.5 M1.05 M1.16 M
Property Plant and Equipment Net359.59 K286.89 K643.15 K3.03 M2.96 M3.19 M
Trade and Non Trade Receivables185.32 K14.83 K28.54 K34.99 K177.24 K191.23 K
Accumulated Retained Earnings Deficit(57 M)(68.85 M)(84.58 M)(104.6 M)(130.65 M)(134.09 M)

Be your own money manager

Our tools can tell you how much better you can do entering a position in Heat Biologics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Focused Opportunities Now


Focused Opportunities

Build portfolios using our predefined set of ideas and optimize them against your investing preferences
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Heat Biologics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Note that the Heat Biologics information on this page should be used as a complementary analysis to other Heat Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Heat Biologics Stock analysis

When running Heat Biologics price analysis, check to measure Heat Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Heat Biologics is operating at the current time. Most of Heat Biologics' value examination focuses on studying past and present price action to predict the probability of Heat Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Heat Biologics' price. Additionally, you may evaluate how the addition of Heat Biologics to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Money Managers
Screen money managers from public funds and ETFs managed around the world
Fundamental Analysis
View fundamental data based on most recent published financial statements
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Is Heat Biologics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Heat Biologics. If investors know Heat Biologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Heat Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Heat Biologics is measured differently than its book value, which is the value of Heat Biologics that is recorded on the company's balance sheet. Investors also form their own opinion of Heat Biologics' value that differs from its market value or its book value, called intrinsic value, which is Heat Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Heat Biologics' market value can be influenced by many factors that don't directly affect Heat Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Heat Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Heat Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Heat Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.